University of Ottawa Heart Institute
Ottawa, Ontario, K1Y4W7, Canada
Location status: Recruiting
Location contact
Keren Mbondo Kasuku, HBSc
CONTACT
Markus Schwerzmann, MD
CONTACT
Markus Schwerzmann, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07585175
Adults with congenital heart disease (CHD) are a growing patient population in need of ongoing specialized care. Lapses in appropriate transition and transfer processes from childhood to adulthood in CHD care can lead to loss in follow up, late detection of new or evolving cardiac complications and negative patient outcomes. Therefore, it is vital that a robust transition and transfer process is established. Through a retrospective study completed recently at the University of Ottawa Heart Institute (UOHI) we have shown that the average wait time to be assessed by an adult congenital heart disease (ACHD) specialist is about 10 months and within this wait period 1 in 8 ACHD patients have a decline in their health.
The goal of this study is to specifically reduce negative patient outcomes during this wait period. We aim to achieve this by (i) establishing a program to ensure early detection of patients at risk of deterioration and (ii) providing additional support to these patients. The program is designed to have a multipronged approach including tools to disseminate concise patient specific information among care providers, maintain open line of communication with patients on the waitlist and promote patient education.
We plan to improve our transition care by creating a multi-pronged transfer program specifically for patients on the wait list composed of a nurse check in, creation of a diagnosis summary, education day and combined pediatric cardiology/ACHD handover videocall (described below). This program is planned as part of our care pathway and will be offered to all patients on the wait list. We intend to document the efficacy of this transition program to improve transition care by assessing patient reported outcomes and clinical outcomes of the patients who consent to complete additional questionnaires.
The multi-pronged program will include the following:
1. ACHD nurse check-in (patient check-in via phone call or zoom from the ACHD nurse within 1 month of receiving referral) - allows early establishment of clinical relationship with the patient, screen for risk factors for deterioration and provision of ACHD clinic contact information to enable open line of communication. Patients considered at risk for deterioration on the wait-list based on this check-in conversation will be triaged for a more urgent first consult at the ACHD clinic. 2. Quick glance diagnosis summary (Electronic on Epic MyChart) - will be created during nurse check in and will be used to disseminate concise patient specific information among health care workers and acts as a reference for the patients. 3. Organization of an ACHD patient education day (half day hybrid event every 6 months) - allows formal introduction to the ACHD team, provides information session on ACHD care and lowers patients' threshold to inform the ACHD team in case of clinical deterioration. 4. Combined pediatric cardiology and ACHD handover video call at time of transfer - allows effective and efficient handover of patient care from pediatric to adult care and facilitates the coordination of care during the transfer period.
These four components of the program work together to provide tools to disseminate concise patient specific information among care providers, maintain open line of communication with patients on the waitlist and promote patient education.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Ottawa, Ontario, K1Y4W7, Canada
Location status: Recruiting
Keren Mbondo Kasuku, HBSc
CONTACT
Markus Schwerzmann, MD
CONTACT
Markus Schwerzmann, MD
PRINCIPAL_INVESTIGATOR
This is a prospective quality improvement study, investigating the effectiveness of a structured multi-pronged transfer program on clinical outcomes and patient-reported outcomes. This program is planned as part of our care pathway and will be offered to all patients on the wait list. Charts of all patients enrolled in this transfer program will be reviewed to assess clinical outcomes. Further voluntary study participation will include an additional survey to assess patient reported outcomes. The patients willing to complete the survey will be consented verbally by the ACHD nurse. The surveys then will be delivered by the nurse using phone or zoom platform to those consenting to participate. Data collection from chart review and surveys will be performed by a research coordinator (KM).
There are 4 components of the transfer program. Groups of patients will be staggered so that the first 50 patients receive 1+2, next 50 patients receive 1+2+3 and the rest of the patients receive 1+2+3+4 as listed below:
Individual component described below:
i. Access to family physician. ii. Assess patient's knowledge on their cardiac condition. iii. Patient' social circumstance. iv. Patient's dental health. v. Patient's lifestyle habits. vi. Any active cardiac symptoms. vii. Need to expedite ACHD cardiologist appointment. If patient meets any of the following criteria, then patient will be flagged as needing expedited cardiologist appointment:
d. Initial assessment of patient reported outcomes (PROs) will be completed in the form of an additional survey for the patients who consent to participate.
Variables to be collected:
Within the first month of being on the ACHD waitlist the following will be completed for all patients (whether or not consenting to participate in the voluntary survey):
During the 1 month ACHD nurse check in, the following information will be collected in the form of a survey (in addition to the standard ACHD nurse check in template) only from those consenting to participate (details attached separately):
At time of first ACHD clinic appointment after completing wait list, the following variables will be collected:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
There are 4 components of the transfer program. Groups of patients will be staggered so that the first 50 patients receive 1+2, next 50 patients receive 1+2+3 and the rest of the patients receive 1+2+3+4 as listed below:
Time frame: 2 years
Number of unexpected hospitalizations related to patient's cardiac condition during the wait period.
Time frame: 2 years
Number of family physician visits related to patient's cardiac condition during the wait period.
Time frame: 2 years
Number of urgent intervention related to the cardiac conditions during the wait period.
Time frame: 2 years
Number of non-planned emergency department visits related to patient's cardiac condition during the wait period.
Time frame: 2 years
Patient reported outcomes, scored form 0-27, with higher scores indicating greater severity
Time frame: 2 years
Patient reported outcomes, scored from 0 to 21, with higher scores indicating greater severity.
Time frame: 2 years
Patient reported outcomes, scored from 5 to 25, with higher scores indicating greater life satisfaction.
Contact information is provided by the study sponsor or research team.
Ottawa Heart Institute Research Corporation
Other
Transition and Transfer of Congenital Heart Disease Care From Pediatrics to Adulthood.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07564882
Cardiovascular Abnormalities, Cardiovascular Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07556185
Acquired Heart Disease, Cardiovascular Abnormalities
Toronto, Ontario, Canada
View Trial DetailsNCT07405333
Cardiovascular Abnormalities, Cardiovascular Diseases
Baghdad, Baghdad Governorate, Iraq
View Trial DetailsNCT06845371
Cardiovascular Abnormalities, Cardiovascular Diseases
Tübingen, Germany
View Trial Details